Top

Published in:

01-10-2021 | Ovarian Cancer | Review Article

Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma

Authors: A. Srivastava, A. Gupta, S. Patidar

Published in: Clinical and Translational Oncology | Issue 10/2021

Abstract

Early diagnosis of ovarian carcinoma is bound to boost the long-term endurance rate of the patients. Most ovarian tumors happen post menopause when the ovaries have no vital operation and therefore irregular ovarian role causes no signs. According to Muinao T. et al. (Heliyon. 5(12):e02826, 2019), if we consider the frequency of ovarian carcinoma to be moderate, a screening technique must accomplish a base specificity of 99.6% and sensitivity of over 75%. The classification and approval of early diagnostic biomarkers explicit to ovarian carcinoma are essentially required. Prevailing methods for early diagnosis of ovarian carcinoma incorporate TVS, biological marker examination, or a blend of the two or other. In recent years, it has been revealed that a combination of at least two biomarkers has beaten single biomarkers in measures for early diagnosis of the illness. In the present document, we survey the ongoing exploration of innovative characteristic methodologies and possible panels of carcinoma biological markers for the early diagnosis of ovarian carcinoma and discuss biomarkers as the plausible apparatus for model improvement and other progressed approaches as an effective alternative to the prevailing methods for early diagnosis of this dreadful disease to evade bogus analysis and inordinate expense.

Adolphi NL, Butler KS, Lovato DM, et al. Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI. Contrast Med Mol Imaging. 2012;7(3):308–19. https://doi.org/10.1002/cmmi.499.CrossRef

Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56. https://doi.org/10.1002/path.2696.CrossRefPubMedPubMedCentral

Barnabas GD, Bahar-Shany K, Sapoznik S, et al. Microvesicle proteomic profiling of uterine liquid biopsy for ovarian cancer early detection. Mol Cell Proteomics. 2019;18(5):865–75. https://doi.org/10.1074/mcp.ra119.001362.CrossRefPubMedPubMedCentral

Chappelear A. About ovarian cancer: johns hopkins ovarian cancer center. In: Hopkinsmedicine.org. 2017. https://www.hopkinsmedicine.org/kimmel_cancer_center/cancers_we_treat/ovarian/about/ (Accessed 15 Dec 2020)

Chatterjee M, Hurley LC, Tainsky MA. Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecol Oncol Rep. 2017;21:37–44. https://doi.org/10.1016/j.gore.2017.06.006.CrossRefPubMedPubMedCentral

Clarke CH, Yip C, Badgwell D, et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 2011;122(3):548–53. https://doi.org/10.1016/j.ygyno.2011.06.002.CrossRefPubMedPubMedCentral

Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193–7.PubMed

Cramer DW, Bast RC, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res. 2011;4(3):365–74. https://doi.org/10.1158/1940-6207.capr-10-0195.CrossRef

Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med. 2008;2(3):291–303. https://doi.org/10.2217/17520363.2.3.291.CrossRefPubMed

10.

Diamandis EP, Scorilas A, Fracchioli S, et al. Human Kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol. 2003;21(6):1035–43. https://doi.org/10.1200/jco.2003.02.022.CrossRefPubMed

11.

Elias KM, Guo J, Bast RC. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903–14. https://doi.org/10.1016/j.hoc.2018.07.003.CrossRefPubMedPubMedCentral

12.

Esteller M. Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors. J Nat Cancer Inst. 2000;92(7):564–9. https://doi.org/10.1093/jnci/92.7.564.CrossRefPubMed

13.

Fazio B, Andrea C, Foti A, et al. SERS detection of biomolecules at physiological pH via aggregation of gold nanorods mediated by optical forces and plasmonic heating. Scientif Rep. 2016;6:1–24. https://doi.org/10.1038/srep26952.CrossRef

14.

Fortner RT, Damms-Machado A, Kaaks R. Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017;147(2):465–80. https://doi.org/10.1016/j.ygyno.2017.07.13.CrossRefPubMed

15.

Gorelik E. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomark Prev. 2005;14(4):981–7. https://doi.org/10.1158/1055-9965.epi-04-0404.CrossRef

16.

Han C, Bellone S, Siegel ER, et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol. 2018;149(3):585–91. https://doi.org/10.1016/j.ygyno.2018.03.050.CrossRefPubMedPubMedCentral

17.

Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374–82. https://doi.org/10.1016/j.ygyno.2008.04.041.CrossRefPubMed

18.

Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355–66. https://doi.org/10.1074/mcp.r400006-mcp200.CrossRefPubMed

19.

Jing X, Wei F, Li J, et al. Diagnostic value of soluble B7–H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion. Clin Respir J. 2017;12(3):986–90. https://doi.org/10.1111/crj.12615.CrossRefPubMed

20.

Kim K, Visintin I, Alvero AB, Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med. 2009;29(1):47–55. https://doi.org/10.1016/j.cll.2009.02.001.CrossRefPubMedPubMedCentral

21.

Kim Y-W, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS ONE. 2012;7(9):e44960. https://doi.org/10.1371/journal.pone.0044960.CrossRefPubMedPubMedCentral

22.

Kong K, Kendall C, Stone N, Notingher I. Raman spectroscopy for medical diagnostics — From in-vitro biofluid assays to in-vivo cancer detection. Adv Drug Deliv Rev. 2015;89:121–34. https://doi.org/10.1016/j.addr.2015.03.009.CrossRefPubMed

23.

Lawicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013;6(1):45. https://doi.org/10.1186/1757-2215-6-45.CrossRefPubMedPubMedCentral

24.

Lockwood S. Ovarian Cancer. HealthyWomen. Published September 16, 2009. https://www.healthywomen.org/condition/ovarian-cancer (Accessed 3 Jan 2021)

25.

Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006;102(2):244–51. https://doi.org/10.1016/j.ygyno.2005.12.011.CrossRefPubMed

26.

Lokshin AE, Yurkovetsky Z, Nolen B, et al. Multimarker assay for early diagnosis of ovarian cancer. Cancer Res. 2006;66:155–155.CrossRef

27.

Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018;151(1):159–65. https://doi.org/10.1016/j.ygyno.2018.08.025.CrossRefPubMed

28.

Lyng FM, Traynor D, Ramos IRM, Bonnier F, Byrne HJ. Raman spectroscopy for screening and diagnosis of cervical cancer. Anal Bioanal Chem. 2015;407(27):8279–89. https://doi.org/10.1007/s00216-015-8946-1.CrossRefPubMed

29.

Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trend Cancer. 2017;3(3):198–213. https://doi.org/10.1016/j.trecan.2017.02.003.CrossRef

30.

Mariño IP, Blyuss O, Ryan A, et al. Change-point of multiple biomarkers in women with ovarian cancer. Biomed Signal Process Control. 2017;33:169–77. https://doi.org/10.1016/j.bspc.2016.11.015.CrossRef

31.

McAlpine JN, El Hallani S, Lam SF, et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol. 2011;120(3):385–92. https://doi.org/10.1016/j.ygyno.2010.12.333.CrossRefPubMed

32.

Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. JNCI J NatCancer Instit. 2001;93(19):1458–64. https://doi.org/10.1093/jnci/93.19.1458.CrossRef

33.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Internat J Women’s Health. 2019;11:287–99. https://doi.org/10.2147/ijwh.s197604.CrossRef

34.

Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomark Prev. 2006;15(9):1641–6. https://doi.org/10.1158/1055-9965.epi-05-0980.CrossRef

35.

Moore RG, Blackman A, Miller MC, et al. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance? Gynecol Oncol. 2019;154(1):150–5. https://doi.org/10.1016/j.ygyno.2019.04.006.CrossRefPubMedPubMedCentral

36.

Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402–8. https://doi.org/10.1016/j.ygyno.2007.10.017.CrossRefPubMed

37.

Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Nat Acad Sci. 2005;102(21):7677–82. https://doi.org/10.1073/pnas.0502178102.CrossRefPubMedPubMedCentral

38.

Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826. https://doi.org/10.1016/j.heliyon.2019.e02826.CrossRefPubMedPubMedCentral

39.

Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15(1):12–34. https://doi.org/10.1186/s12943-016-0536-0.CrossRef

40.

National Ovarian Cancer Coalition - NOCC Staff. Types and Stages - National Ovarian Cancer Coalition. Ovarian.org. Published 2021. https://www.ovarian.org/about-ovarian-cancer/what-is-ovarian-cancer/types-a-stages. (Accessed 22 Jan 2021)

41.

Nebgen DR, Lu KH, Bast RC. Novel approaches to ovarian cancer screening. Curr Oncol Rep. 2019;21(8):12–53. https://doi.org/10.1007/s11912-019-0816-0.CrossRef

42.

Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009;200(6):6391–5. https://doi.org/10.1016/j.ajog.2008.12.042.CrossRef

43.

Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis. Biosens Bioelectron. 2015;73:146–52. https://doi.org/10.1016/j.bios.2015.05.051.CrossRefPubMed

44.

Paraskevaidi M, Ashton KM, Stringfellow HF, et al. Raman spectroscopic techniques to detect ovarian cancer biomarkers in blood plasma. Talanta. 2018;189:281–8. https://doi.org/10.1016/j.talanta.2018.06.084.CrossRefPubMed

45.

Patel KM, Tsui DWY. The translational potential of circulating tumour DNA in oncology. Clin Biochem. 2015;48(15):957–61. https://doi.org/10.1016/j.clinbiochem.2015.04.005.CrossRefPubMed

46.

Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–54. https://doi.org/10.4065/mcp.2010.0099.CrossRefPubMedPubMedCentral

47.

Peng D, Xu T, Mason TJ, Wu W. A study of ovarian cancer biomarker amplification using ultrasound for early stage detection. Ultrasonics. 2014;54(2):451–4. https://doi.org/10.1016/j.ultras.2013.05.014.CrossRefPubMed

48.

Pinsky PF, Zhu CS. Building multi-marker algorithms for disease prediction–-the role of correlations among markers. Biomarker Insights. 2011;6:BMIS7513. https://doi.org/10.4137/bmi.s7513.CrossRef

49.

Sarojini S, Tamir A, Lim H, et al. Early detection biomarkers for ovarian cancer. J Oncol. 2012;22:1–15. https://doi.org/10.1155/2012/709049.CrossRef

50.

Simon I, Zhuo S, Corral L, et al. B7–H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Can Res. 2006;66(3):1570–5. https://doi.org/10.1158/0008-5472.can-04-3550.CrossRef

51.

Skates SJ, Horick N, Yu Y, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–3, CA 72–4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22(20):4059–66. https://doi.org/10.1200/jco.2004.03.091.CrossRefPubMed

52.

Su F, Lang J, Kumar A, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insight. 2007;2:369–75.CrossRef

53.

Tcherkassova J, Abramovich C, Moro R, et al. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumor Biology. 2011;32(4):831–8. https://doi.org/10.1007/s13277-011-0186-1.CrossRefPubMed

54.

Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14(4):1065–72. https://doi.org/10.1158/1078-0432.ccr-07-1569.CrossRefPubMed

55.

Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9:1–34. https://doi.org/10.1186/s13073-017-0500-7.CrossRef

56.

Xiang H, Huang R, Cheng J, et al. Value of three-dimensional contrast-enhanced ultrasound in the diagnosis of small adnexal masses. Ultrasound Med Biol. 2013;39(5):761–8. https://doi.org/10.1016/j.ultrasmedbio.2012.11.008.CrossRefPubMed

57.

Yokoi A, Yoshioka Y, Hirakawa A, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8(52):89811–23. https://doi.org/10.18632/oncotarget.20688.CrossRefPubMedPubMedCentral

58.

Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28(13):2159–66. https://doi.org/10.1200/jco.2008.19.2484.CrossRefPubMedPubMedCentral

59.

Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019;43(2):135–44. https://doi.org/10.1016/j.currproblcancer.2018.06.001.CrossRefPubMed

60.

Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Can Res. 2004;64(16):5882–90. https://doi.org/10.1158/0008-5472.can-04-0746.CrossRef

61.

Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE. 2013;8(11):e77853. https://doi.org/10.1371/journal.pone.0077853.CrossRefPubMedPubMedCentral

62.

Papanikolaou G, Gkouvatsos K, Pantopoulos K. Transferrin. Encycloped Signal Mole . 2018;4:5615–23. https://doi.org/10.1007/978-3-319-67199-4_101940.CrossRef

63.

Robbins J. Transthyretin from discovery to now. Clin Chem Lab Med. 2002;5:40–112. https://doi.org/10.1515/cclm.2002.208.CrossRef

64.

Wikipedia Contributors. ApoA-1 Milano. Wikipedia. Published December 30, 2020. https://en.wikipedia.org/wiki/ApoA-1_Milano#:~:text=5%20Subsequent%20Development-,Discovery,small%20village%20in%20northern%20Italy. (Accessed 28 Jan 2021)

65.

Smith JB, Stashwick C, Powell DJ. B7–H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol. 2014;134(1):181–9. https://doi.org/10.1016/j.ygyno.2014.03.553.CrossRefPubMedPubMedCentral

66.

Ribatti D. From the discovery of vascular endothelial growth factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara. Int J Dev Biol. 2011;55(4–5):383–8. https://doi.org/10.1387/ijdb.103216dr.CrossRef

67.

Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park, NY). 2013;27(6):548–556. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085777/. (Accessed 28 Jan 2021)

68.

Wikipedia Contributors. Osteopontin. Wikipedia. Published January 4, 2021. https://en.wikipedia.org/wiki/Osteopontin. (Accessed 28 Jan 2021)

69.

Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007;1(4):513–23. https://doi.org/10.2217/17520363.1.4.513.CrossRefPubMed

70.

Wikipedia Contributors. Carcinoembryonic antigen. Wikipedia. Published January 2, 2021. https://en.wikipedia.org/wiki/Carcinoembryonic_antigen. (Accessed 28 Jan 2021)

71.

Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol. 2006;168(1):93–103. https://doi.org/10.2353/ajpath.2006.050601.CrossRefPubMedPubMedCentral

Title: Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma
Authors: A. Srivastava
A. Gupta
S. Patidar
Publication date: 01-10-2021
Publisher: Springer International Publishing
Keywords: Ovarian Cancer
Ovarian Cancer
Biomarkers
Published in: Clinical and Translational Oncology / Issue 10/2021
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-021-02604-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2021

Long-term results of a randomized partial irradiation trial compared to whole breast irradiation in the early stage and low-risk breast cancer patients after conservative surgery

Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression

Scapular winging in surgical treatment of breast cancer, prospective study to optimize the follow-up protocol

Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA

Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study

Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer